Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470202 | 0.89 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL2471244 | 0.86 | EGLN3 (0.52) | EGLN3EGLN1 | |
| SCHEMBL2491080 | 0.81 | DHPS (0.38) | EGLN3PDE10AKDM4EKMT2A | |
| SCHEMBL2471513 | 0.80 | EGLN3 (0.52) | EGLN3EGLN1 | |
| SCHEMBL2469234 | 0.80 | EGLN2 (0.45) | EGLN3EGLN1EGLN2 | |
| SCHEMBL2471828 | 0.78 | EGLN1 (0.45) | EGLN3EGLN1EGLN2KDM4EKMT2A | |
| SCHEMBL2470944 | 0.75 | EGLN1 (0.53) | EGLN3EGLN1KDM4EMEN1KMT2A | |
| SCHEMBL2472669 | 0.74 | EGLN1 (0.43) | EGLN3EGLN1 | |
| SCHEMBL2469945 | 0.74 | HIF1A (0.47) | EGLN3EGLN1 | |
| SCHEMBL2470740 | 0.74 | CASP1 (0.42) | EGLN3EGLN1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | claimed |
| CN-105037323-A | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-11-11 | — | — | CN | claimed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | claimed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | claimed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | claimed |
| CN-102272117-A | Benzothiopyran derivatives as HIF hydroxylase inhibitors | — | 2011-12-07 | — | — | CN | claimed |
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-105037323-A | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-11-11 | — | — | CN | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| CN-102272117-B | Benzothiopyran derivatives as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-06-17 | — | — | CN | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| CN-102272117-A | Benzothiopyran derivatives as HIF hydroxylase inhibitors | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN3 4/4885EGLN1 6/4885EGLN2 3/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN3 4/4885EGLN1 6/4885EGLN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.